X4 Pharmaceuticals
XFOR
50 hedge funds and large institutions have $113M invested in X4 Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 10 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
0.04% more ownership
Funds ownership: 2.28% → 2.33% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less capital invested
Capital invested by funds: $118M → $113M (-$5.57M)
6% less funds holding
Funds holding: 53 → 50 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
+$4.75M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$3.14M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.45M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.45M |
| 5 |
State Street
Boston,
Massachusetts
|
+$949K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4.81M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.45M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.91M |
| 4 |
BCP
Berylson Capital Partners
Boston,
Massachusetts
|
-$1.03M |
| 5 |
Millennium Management
New York
|
-$471K |
XFOR Hedge Fund Activity: Q1 2020 in Review
50 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2020, worth a combined $113M — down 4.7% from $118M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of XFOR and 7 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 18 added.
The largest buyer was Axa, opening a new position worth an estimated $4.75M. The largest seller was Deerfield Management, exiting entirely with an estimated $4.81M sold.
- 50 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2020, down from 53 in Q4 2019.
- Funds reported $113M of X4 Pharmaceuticals stock for Q1 2020, down 4.7% quarter-over-quarter.
- 7 funds opened new X4 Pharmaceuticals positions in Q1 2020 and 10 closed out, a net change of -3 holders.
- The largest X4 Pharmaceuticals buyer in Q1 2020 was Axa, an estimated $4.75M added.
- The largest X4 Pharmaceuticals seller in Q1 2020 was Deerfield Management, an estimated $4.81M sold.
Based on aggregated 13F filings for Q1 2020.